AliveCor Taps Ex-Google (GOOG) Exec as CEO

AliveCor Announces Appointment of Chief Executive Officer

SAN FRANCISCO, Nov. 11, 2015 /PRNewswire/ -- AliveCor, Inc., the leader in FDA-cleared ECG technology for smartphones, announced today the appointment of former Google executive, Vic Gundotra as Chief Executive Officer, effectively immediately, replacing Euan Thomson, the company's interim Chief Executive Officer.

Thomson joined the Board of Directors in January 2013 and became AliveCor's interim Chief Executive Officer in August 2013. During his tenure Thomson grew the company through a defining period, including expanded FDA and CE mark clearances, the launch of three algorithms, and recently surpassing four million ECGs recorded into the AliveCor database. As of October 2015 AliveCor received more than 350,000 electrocardiograms (ECGs) and reported more than 20,000 regular users. Additionally, 30% of AliveCor patients have received an instant atrial fibrillation (AFib) detection using the AF Detector, an algorithm to detect AFib in an ECG.

"My time at AliveCor has been an important and fulfilling chapter in my career. No one has done what we are doing. I am thankful for the opportunity to help develop products that are helping people across the world," said Thomson. "I am pleased to welcome Vic who brings years of experience spanning consumer and technology products that will be of great value as AliveCor works to expand and diversify into different business models."

"I am thrilled to become part of the AliveCor team. What they have achieved throughout the past four years is tremendous," said Vic Gundotra, chief executive officer of AliveCor. "Being able to understand what is going on inside heart disease through data analytics and machine learning has the potential to change the way we think of and participate in our healthcare. I am looking forward to being on the forefront of consumerizing medicine and working with an extremely intelligent team with innovative products."

Prior to joining AliveCor Vic served as Senior Vice President at Google from 2011 until April 2014, heading up the company's social initiatives. He joined Google in 2007 as vice president of engineering, where he was responsible for mobile application development, including product management and marketing. Prior to Google, Vic spent 15 years at Microsoft, where he worked on a variety of products and operating systems. He was recognized by MIT as a "Young Innovator under 35" for his work in sparking Microsoft's change from Win32 to the .NET programming model. While at Microsoft Vic also served as general manager of Microsoft's developer outreach efforts worldwide, including evangelism and strategy for products like Windows Vista, Visual Studio, Microsoft Office, Microsoft CRM and Windows Mobile.

About AliveCor, Inc.
AliveCor Inc. is a global innovator in mobile technology for heart health. AliveCor works with health systems to help identify patients with undiagnosed heart conditions before potentially life-threatening conditions, like stroke, can occur. AliveCor helps diagnosed patients work with their physician to monitor, track and manage their condition in new ways. AliveCor is a privately-held company headquartered in San Francisco, Calif. For more information, please visit

AliveCor is a trademark of AliveCor, Inc., registered in the U.S. and other countries

Media Contact:
Rebecca Phillips
+1 (415) 795-9807
[email protected]

To view the original version on PR Newswire, visit:

SOURCE AliveCor, Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.